Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Kalofonos
Haralabos P
HP
Division of Oncology, Department of Medicine, University Hospital of Patras, Rion, Patras, Greece. kalofon@med.upatras.gr
Papakostas
Pavlos
P
Makatsoris
Thomas
T
Papamichael
Demetrios
D
Vourli
Georgia
G
Xanthakis
Ioannis
I
Aravantinos
Gerasimos
G
Papadimitriou
Christos
C
Pentheroudakis
George
G
Varthalitis
Ioannis
I
Samelis
George
G
Syrigos
Kostas N
KN
Xiros
Nikolaos
N
Stavropoulos
Michalis
M
Kosmidis
Paris
P
Christodoulou
Christos
C
Linardou
Helen
H
Skondra
Maria
M
Pectasides
Dimitrios
D
Economopoulos
Theofanis
T
Fountzilas
George
G
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin